导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.56% | 4400/4773 |
| 近一周 | -3.50% | 4063/5458 |
| 近一月 | -3.02% | 1825/5421 |
| 近一季 | -6.58% | 3271/5205 |
| 近半年 | -18.00% | 4289/4920 |
| 近一年 | -23.49% | 4048/4361 |
| 近两年 | 3.10% | 2859/2954 |
| 近三年 | -30.63% | 2221/2253 |
| 成立以来 | -32.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-9.06% 4341/4961 |
-11.67% 4322/5312 |
- - |
- - |
| 2025 | 2.82% 3165/4813 |
-5.05% 3253/3635 |
-1.29% 3139/4076 |
19.82% 2092/4524 |
-8.44% 3921/4813 |
| 2024 | -0.10% 2098/3463 |
-8.03% 2211/2808 |
-10.33% 2440/3014 |
31.83% 106/3129 |
-8.12% 2831/3463 |
| 2023 | -24.28% 1968/2656 |
-5.03% 2131/2280 |
-8.36% 1988/2385 |
1.01% 325/2515 |
-13.87% 2472/2655 |
| 2022 | -9.03% 164/2207 |
7.87% 24/1919 |
-8.42% 1897/2016 |
-7.54% 133/2113 |
-0.40% 1601/2208 |
| 2021 | 4.72% 565/1822 |
-0.43% 365/1255 |
1.25% 1063/1330 |
3.15% 417/1466 |
0.69% 1076/1822 |
| 2020 | -6.96% 982/1250 |
-12.55% 893/1028 |
8.93% 806/1067 |
4.68% 946/1164 |
-6.69% 1146/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏中证全指房地产ETF联接C VS. 长安沪深300非周期A(740101) |